<DOC>
	<DOCNO>NCT02385955</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety myeloablative double unit umbilical cord blood transplantation ( dUCBT ) adult patient hematologic malignancy . Two myeloablative conditioning regimen use study : ( 1 ) total body irradation ( TBI ) , cyclophosphamide , cytarabine , ( 2 ) thiotepa , busulfan , fludarabine .</brief_summary>
	<brief_title>Phase II Study Myeloablative Double Unit Umbilical Cord Blood Transplantation Adult Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients hematologic malignancy require hematopoietic stem cell transplantation : ( 1 ) high risk acute myeloid leukemia remission , ( 2 ) high risk acute lymphoblastic leukemia remission , ( 3 ) IPSS intermediate2 , high , transfusiondependent myelodysplastic syndrome Patients suitable cord blood unit dUCBT Patients ECOG performance status 01 Patients adequate organ function : lung , kidney , liver , heart , etc . Informed consent Patients receive hematopoietic stem cell transplantation HLAmatched sibling unrelated donor Patients antiHLA antibody Patients evidence central nervous system ( CNS ) involvement disease Patients uncontrolled diabetes Patients uncontrolled hypertension Patients evidence active infection Positive human immunodeficiency virus ( HIV ) Previous history malignancy within 5 year ( Basal cell carcinoma skin , cervical carcinoma situ , differentiate thyroid carcinoma curative resection permit . ) Women pregnant breastfeeding Patients previous history allogeneic stem cell transplantation Patients major psychotic disorder drug/alcohol abuser Inappropriate patient accord investigator ' opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>